SNS-032 (BMS-387032) is a selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9 that regulate the cell cycle and transcription. It has IC50 values of 38 nM for Cdk2, 62 nM for Cdk7, and 4 nM for Cdk9. SNS-032 was in clinical trials for a variety of cancers including chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
Selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9
Inhibitors of cyclin-dependent kinases (Cdks) have been reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9, which control transcription. Here we studied the novel Cdk inhibitor SNS-032, which exhibits potent and selective inhibitory activity against
Nature chemical biology, 14(2), 163-170 (2017-12-19)
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of
Cancer chemotherapy and pharmacology, 76(1), 105-116 (2015-05-20)
ATP-binding cassette (ABC) transporters play an important role in multidrug resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin-dependent kinase inhibitors (CDKi) AT-7519, flavopiridol and SNS-032 with the following ABC transporters in vitro: P-glycoprotein (ABCB1), breast cancer resistance
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
